GT Biopharma, Inc.

GTBP Healthcare Biotechnology

In the quarter to June 2026, EPS grew 98.9% and free cash flow fell 41.3%, each against the same quarter a year earlier.

7.03 0.33 −4.48%
Market cap
$15.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−5138.41
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(1,205.42%) (1,674.31%) (1,122.83%) 102.03%
ROA
(554.30%) (558.42%) (585.46%) (176.27%)
ROIC
(1,746.37%) 0.00% 0.00% 0.00%
Return on Tangible Assets
(1,023.60%) (595.28%) (488.68%) (318.86%)
Free Cash Flow per Share
(72.09) (58.57) (10.88) (9.29)
Free Cash Flow
(11.36) (12.91) (13.18) (14.43)
Other line items
Cash ROIC
(202.12%) (101.75%) (79.41%) (167.30%)
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Interest Coverage
— — (27.11) (47.49)
Operating CF/Net income
0.37 0.37 0.36 1.27
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(72.09) (58.57) (10.88) (9.29)
Capex per Share
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates